The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

Sanofi's sale of its consumer division to CD&R could be blocked if government requirements on jobs, production, and R&D are unmet. Political opposition to the deal has surged, citing risks to ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US ...

The French pharmaceutical group’s board is scheduled to meet to discuss the planned transaction and finalize measures with CD&R to protect jobs and local plants, the people said, asking not to ...

In September, Bloomberg reported that Sanofi had received two separate bids from CD&R and rival PAI Partners for the Opella unit. CD&R has kept away interest from rival PAI Partners for the unit ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Clayton Dubilier & Rice is close to completing a deal to buy control of Sanofi’s (NASDAQ:SNY) consumer health unit after signing social commitments with the French government, Bloomberg News ...

The move to enter exclusivity with CD&R came after Sanofi's disclosure that it had opened talks with the New York-based private-equity group sparked a political debate in France over the future of ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US firm ...